title: A male with primary breast lymphoma.
authors.affiliation: Department of Hematology, Osaka Red Cross Hospital, Osaka, Japan. ymiura@osaka-med.jrc.or.jp
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Miura
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Nishizawa
authors.forename: Hitomi
authors.initials: H
authors.lastname: Kaneko
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Watanabe
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Tsudo
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D018567:Breast Neoplasms, Male / Q000188:drug therapy / Q000473:pathology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone